Gregor
DIAGNOSTICS

Outreach Presentation

January 2025

Revolutionizing Prostate Cancer Detection

The Problem?

- Prostate cancer remains the most diagnosed cancer in American men, with **~300,000 new cases** each year and **~35,000 deaths annually**

- Traditional diagnostics, such as PSA tests, often result in unnecessary procedures, causing patient anxiety and healthcare inefficiencies

- Current diagnostic methods have not meaningfully moved the needle in over a decade in terms of catching prostate cancer early and saving lives

---

Prostate cancer is leading cause of cancer in American men, with **~300K cases diagnosed annually**

2nd leading cause of cancer deaths in American men, with **~35K deaths annually**

1 in 8 men will be diagnosed with prostate cancer during their lifetime

Poor diagnostic landscape causes patient confusion and forces a difficult choice between **watchful waiting and overtreatment of indolent cancers**

Gregor DIAGNOSTICS

The Gregor Diagnostics Solution

- Gregor Diagnostics is revolutionizing prostate cancer detection with a groundbreaking, non-invasive test using semen biomarkers

- Gregor offers the potential to improve PSA screening and reduce unnecessary biopsies by leveraging the abundance of prostate cancer biomarkers found in semen

- The platform can differentiate between benign, low-grade, and high-grade cancers, reducing unnecessary procedures and overtreatment, while detecting aggressive cancers early

- This precision eliminates the risk of overtreatment and unnecessary biopsies while detecting aggressive cancers early when they are most treatable

- Test shows high sensitivity and specificity, with potential to drive a ~70% reduction in unnecessary biopsies and improved diagnostic accuracy

Gregor
DIAGNOSTICS

Series A Investment Summary

Gregor is seeking **$20M in Series A funding** to scale platform development, conduct clinical validation, and initiate commercialization in the U.S. market.

Insiders and existing shareholders have signaled commitment for a significant amount, and combined with interest from other investors, **~50% of the current round is already soft-circled**

- ✓ **Proven Team in Diagnostics:** *Extensive expertise in diagnostics, biomarker discovery, and commercialization, led by a seasoned team with deep experience in cancer detection and healthcare innovation*

- ✓ **$2B+ U.S. Market Opportunity:** *Addressing unmet needs in prostate cancer diagnostics, with a potential market exceeding $2 billion, driven by advanced screening, active surveillance, and growing patient populations*

- ✓ **Innovative Platform:** *First-of-kind semen biomarker test, validated for high accuracy, telemedicine compatibility, and non-invasive at-home sample collection, offering a patient-centric solution*

- ✓ **Reducing Unnecessary Biopsies:** *Platform provides best-in-class sensitivity and specificity, significantly cutting unnecessary biopsies by ~70%*

- ✓ **Near-Term Commercial Launch:** *Gregor's Reflex test is on track for a 2026 launch*

- ✓ **Future Expansion Opportunities:** *Active surveillance monitoring and companion diagnostics for therapeutic support, with further potential for biorepository data mining*

Gregor DIAGNOSTICS

Proven Team with Decades of Diagnostic and Oncology Expertise

Combined >80 years of experience

Lauren Tyra, PhD

Chief Executive Officer

Chief Scientific Officer – GPG Ventures

Community leader

PhD, UT Southwestern

Duncan Whitney, PhD

Chief Scientific Officer

Former Exact Sciences, J&J, Veracyte, and Allegro Diagnostics

>25 years oncology Dx experience

PhD, MIT

Tobias Zutz, MS

Chief Technology Officer, Founder

Former Exact Sciences, Primorigen Biosciences

MS, University of Wisconsin

Michael Brawer, MD

Medical Advisor

Former MDxHealth, Myriad Genetics, University of Washington

>40 years focused on prostate cancer

MD, UCLA

Gregor DIAGNOSTICS

The Gregor Diagnostics Solution: Semen-Based Testing

Groundbreaking, non-invasive method for detecting prostate cancer with higher accuracy than traditional tests while significantly reducing unnecessary biopsies

Benefits of Semen Sample for Diagnostics

✓ **Non-invasive liquid biopsy**

✓ **Detect cancer vs benign OR low-grade vs high-grade**

✓ **Well-established for fertility**

✓ **Most men 50-70 can produce a semen sample**

*Prostate cancer biomarkers are highly abundant in semen*

Preliminary validation far surpasses urine and blood tests for accuracy and biopsy avoidance

Non-invasive, at-home sample collection, no rectal exam necessary

Gregor
DIAGNOSTICS

Addressing Gaps in the Prostate Cancer Diagnostic Journey

Gregor Diagnostics is revolutionizing prostate cancer diagnostics by reducing unnecessary biopsies and best-in-class accuracy

Development Pipeline

Gregor Diagnostics is developing multiple tools for prostate cancer detection and monitoring

Seminal Fluid Collection	Pathology	Molecular Biomarker Selection	AI/ML
Men indicated for biopsy	Biopsy, RP pathology collected	mRNA, miRNA, meDNA, etc.	Develop multiple classifiers

Reflex Test

Active Surveillance Test

Therapeutic Applications

Sequenced Specimens from Gregor's Biorepository

Well-matched validation set for biomarker studies

**The table shows the breakdown of subjects in the training and validation sets by:**

✓ Demographics (age, race, and family history of PCa)

✓ PSA score at the time of biopsy and sample collection

✓ Vasectomy status (important for semen sample testing)

✓ Cancer status and ISUP grade, following biopsy

All categories were found to be well-matched ($p \ll 0.05$) between training and validation sets

| Evaluable Subject Population	Evaluable Samples		Training Cohort		Validation Cohort	
# Subjects (% Cohort)	279	(NA)	199	(NA)	80	(NA)
No PCa	128	(46%)	96	(48%)	32	(40%)
PCa	151	(54%)	103	(52%)	48	(60%)
Median Age	62		63		61	
PCa Family History	**#**	**%[b]**	**#**	**%[b]**	**#**	**%[b]**
Yes	70	25%	51	26%	19	24%
No	200	72%	140	70%	60	75%
Unknown	9	3%	8	4%	1	1%
Race/Ethnicity	**#**	**%[b]**	**#**	**%[b]**	**#**	**%[b]**
Caucasian	236	85%	168	84%	68	85%
African American	27	10%	19	10%	8	10%
Hispanic	11	4%	8	4%	3	4%
Asian	1	0%	0	0%	1	1%
Other	3	1%	3	2%	0	0%
Unknown or Not Reported	1	0%	1	1%	0	0%
Biopsy ISUP Grade Group	**#**	**%[b]**	**#**	**%[b]**	**#**	**%[b]**
Benign	128	46%	96	48%	32	40%
GG1	72	26%	49	25%	23	29%
GG2	37	13%	23	12%	14	18%
GG3	25	9%	18	9%	7	9%
GG4	12	4%	9	5%	3	4%
GG5	5	2%	4	2%	1	1%
Vasectomy	**#**	**%[b]**	**#**	**%[b]**	**#**	**%[b]**
Yes	76	27%	60	30%	16	20%
No	203	73%	139	70%	64	80%

Gregor DIAGNOSTICS

Reflex 1+ Classifier Trained to Provide High Sensitivity for Detection

Gregor Diagnostic's Reflex 1+ classifier training and cross-validation show potential for high sensitivity and accuracy in detecting prostate cancer with or without the addition of clinical data required by other tests

Average AUC: 0.8547

Commercial Urine Diagnostic Tests

EPI	AUC: 0.70 (0.67 - 0.73)
PCPT	AUC: 0.62 (0.59 - 0.66)
ERSPC	AUC: 0.59 (0.56 - 0.63)
PSA	AUC: 0.56 (0.53 - 0.60)

Existing urine diagnostics exhibit low-to-moderate performance, with none achieving ideal accuracy

- ✓ We measure how good models are by measuring the area-under-the-curve (AUC)

- ✓ Many different types of classification algorithms were evaluated in parallel in the training set

- ✓ Models were built using gene-expression with and without clinical features (age, race, PSA, PSA Density*, family history, and previous biopsy result)

- ✓ Overall accuracy was evaluated using ROC curves and maximizing the AUC

- ✓ Training exercises have shown consistent results in top differentially expressed genes and similar AUC results using different machine-learning models and alternative feature selection methods

- ✓ Gene-expression only model training meets our pre-defined target specifications, and the model was locked

**PSA Density is included here among clinical variables although it is not included in clinical variables in prostate cancer prevention trial risk calculator (PCPTRC)*

Gregor
DIAGNOSTICS

# Reflex 1+ Classifier Gives Reproducible Results in Independent Training and Validation Cohorts

Gregor Diagnostic's Reflex 1+ molecular classifier delivers highly reproducible and accurate results in holdout test set

AUC = 0.90

Sensitivity = 91.7%
Specificity = 68.8%

- The test has high sensitivity – leading to **few false-negative results**

- Specificity is also high – leading to **avoidance of ~70% of unnecessary biopsies**

- High negative predictive value for high-grade cancer – **NPV = 98.8% for GG3+ in this intended-use population**

- The test results are **highly reproducible between the cross-validation testing and the independent test set**

- **Meets target product profile (TPP) and outperforms any currently marketed tests**

The Competition: What Sets Us Apart?

Platform significantly outperforms currently marketed blood and urine tests

Currently marketed Blood and Urine tests

Gregor advantages:
- ✓ **Best-in-class accuracy**
- ✓ **No rectal exam**
- ✓ **Telemedicine friendly**
- ✓ **At-home sample collection**

Based on Gregor's best-in-class Reflex 1+ results and published results for competitive Reflex tests.

At-Home Sample Collection Improves Continuum of Care

Convenient, patient-centric test for enhanced care and accessibility

Physician prescribes test

Patient completes sample at home

Report returned to clinician for patient counseling

Patient returns kit to Gregor

Gregor lab performs test

Less invasive

Cost effective

Patient friendly

Repeatable testing

The Kit

*At-home collection kit allows for convenient, private patient sample collection*

Stabilization buffer designed to allow for ambient temperature shipping from the patient's home to Gregor's lab

Tested with non-cancer patients in 2024

Kit partner has developed saliva collection kits that are similarly used for at-home collection, over 33 million used to date

Attractive, Near-Term Platform Opportunity

Gregor's Reflex test is on track for a 2026 launch, with future expansion into active surveillance monitoring

Feasibility → **Clinical Validity** → **Launch**

1 Reflex

2 Active Surveillance Monitoring

2026 LDT Launch

Future Expansion Opportunities:

✓ **Treatment Support (companion diagnostics, therapeutic monitoring)**

✓ **Biorepository data mining**

Total Addressable Market (U.S.)

Active Surveillance and Reflex markets combine for >$2 billion annual TAM at current screening and diagnosis rates

(37.1% screening, ~300k newly diagnosed annually)

Total

>$2 Billion and growing

Reflex

$1.3 Billion

Active Surveillance
Low-risk only

$714 Million

Conclusion

Gregor is seeking **$20M in Series A funding** to scale platform development, conduct clinical validation, and initiate commercialization in the U.S. market.

Insiders and existing shareholders have signaled commitment for a significant amount, and combined with interest from other investors, **~50% of the current round is already soft-circled**

- ✓ **Proven Team in Diagnostics:** *Extensive expertise in diagnostics, biomarker discovery, and commercialization, led by a seasoned team with deep experience in cancer detection and healthcare innovation*

- ✓ **$2B+ U.S. Market Opportunity:** *Addressing unmet needs in prostate cancer diagnostics, with a potential market exceeding $2 billion, driven by advanced screening, active surveillance, and growing patient populations*

- ✓ **Innovative Platform:** *First-of-kind semen biomarker test, validated for high accuracy, telemedicine compatibility, and non-invasive at-home sample collection, offering a patient-centric solution*

- ✓ **Reducing Unnecessary Biopsies:** *Platform provides best-in-class sensitivity and specificity, significantly cutting unnecessary biopsies by ~70%*

- ✓ **Near-Term Commercial Launch:** *Gregor's Reflex test is on track for a 2026 launch*

- ✓ **Future Expansion Opportunities:** *Active surveillance monitoring and companion diagnostics for therapeutic support, with further potential for biorepository data mining*

Gregor
DIAGNOSTICS